Specifically, TP53 mutations are significantly enriched in sarcomas (p = 1.00 × 10−7), including hemangiosarcoma (p = 5.82 × 10−6) and osteosarcoma (p = 2.92 × 10−2), but depleted in carcinoma (p = 2.58 × 10−7), including anal sac carcinoma (p = 5.73 × 10−4) (Fig. 6a). This evidence concerns the gene TP53 and carcinoma.